Therefore, a vigorous research effort is needed to seek a feasible way to examine EGFR-Arf1 activity in subsets of HNSCC patients in order to better assess or predict the clinical outcomes of HDAC inhibitors. This evidence concerns the gene HDAC9 and head and neck squamous cell carcinoma.